That is correct; results will likely not be available until late autumn 2027.
When asked about the most important milestones the company will deliver over the next 18 months, Bono replied:
- Getting the first patient into the BEXMAB2 study later this autumn
- The study enrolls patients efficiently so that an efficacy readout from 90 randomized patients is achieved in autumn 2027
- Efficacy results for solid tumors will arrive in H2 2027
Naturally, the most important news is the publication of the BEXMAB2 study results in late autumn 2027.
The company has previously issued a press release for events like point 1. The status of point 2 is likely more of an internal company matter, but it can be inquired about at the spring 2027 Annual General Meeting at the latest. The start of the studies in point 3 is still awaiting regulatory decisions, but it is possible that approval will be granted during the first half of 2026.
A press release may also be issued then, providing an estimate of the start date.